The latest: Pharmaceutical services outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) forecast it will post yearly revenue growth of 63% to 65% in the second quarter, according to a business update released on Sunday.

Looking up: The company’s operations in Shanghai have resumed, following a two-month lockdown in the city. WuXi AppTec added it is confident of achieving full-year revenue growth of 65% to 70% as its business continuity plans are executed.

Take Note: The company reported 71.2% year-on-year revenue growth in the first quarter, meaning the second-quarter forecast represents a slowdown.

Digging Deeper: Founded in December 2000, WuXi AppTec is a Chinese pharmaceutical outsourcing services provider, covering the entire industry chain from drug discovery to commercialization. The company has grown rapidly on big demand from both foreign and domestic drug developers for outsourced R&D and manufacturing services for their activity in the fast-growing China market. The company’s second-quarter forecast would mark its ninth consecutive quarter of revenue growth.

Market Reaction: WuXi AppTec shares opened up 0.4% in Hong Kong on Monday and moved steadily higher from there, closing up 8.4% at HK$98.95 at the midday break. But the stock still trades near the low end of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Qudian abandons last mile delivery

Qudian: A slow-motion privatization?

The company said it is contemplating winding down its last-mile delivery service after stiff competition caused its revenue to plunge in the first quarter Key Takeaways: Qudian’s revenue fell by…
Yeahka secures bridgehead in U.S. payments market

Yeahka secures bridgehead in U.S. payments market

The Chinese fintech has cleared one of many regulatory hurdles to enter the U.S. digital payments business after gaining a state-level operating license Key Takeaways: After getting U.S. federal clearance,…
Sante makes infant nutritional products

Sainte Nutritional nurtures Hong Kong IPO

The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutritional has filed…